Euroapi: posts strong H1 earnings growth
(CercleFinance.com) - The small molecules group and Sanofi spin-off, Euroapi reports H1 2023 net income of E62.
8m, well above the E16.7m a year ago, as well as Core EBITDA of E62.5m, representing a margin of 12.6% compared with 14.5% in H1 2022.
Sales rose by 2.6% to E496.6m, with API Solutions remaining flat (+0.2%) and CDMO growing by 9.8%. The falling sales to Sanofi were more than offset by increased sales to other clients.
Management said that based on its H1 performance, it is confident in its ability to achieve its targets for FY 2023, as well as its medium-term outlook.
Copyright (c) 2023 CercleFinance.com. All rights reserved.